Referências: 1. British Society of Gastroenterology consensus guidelines on the management of inflammatory bowel disease in adults. Lamb CA, et al. Gut 2019;68: s1–s106. doi:10.1136/gutjnl-2019-318484 s3. 2. Cohn’s Disease: Diagnosis and Management. Am Fam Physician. 2018 Dec 1;98(11):661-669. 3. Protocolo Clínico e Diretrizes Terapêuticas da Doença de Crohn. Conitec 2017. 4. Vedolizumabe (Entyvio®) para Doença de Crohn. Conitec 2019. 5. ECCO Guidelines on Therapeutics in Crohn’s Disease: Medical Treatment. Journal of Crohn’s and Colitis, 2020, 4–22 doi:10.1093/ecco-jcc/ jjz180. 6. Hazlewood GS, Rezaie A, Borman M, et al. Comparative effectiveness of immunosuppressants and biologics for inducing and maintaining remission in Crohn’s disease: a network meta-analysis. Gastroenterology 2015; 148:344–54.e5; quiz e14–5. 7. Kawalec P, Moćko P. An indirect comparison of ustekinumab and vedolizumab in the therapy of TNF-failure Crohn’s disease patients. J Comp Eff Res 2018; 7:101–1. 88
RkJQdWJsaXNoZXIy MjcxMg==